BioNTech is navigating a sharp post-pandemic revenue decline, with 2026Q2 sales down 59.5% YoY to $105.6M, while aggressively investing in its oncology pipeline. The company's fortress balance sheet, featuring $9.7B in cash and a 0.02 debt-to-equity ratio, pro...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue has collapsed to $105.6M in 2026Q2, down 59.5% YoY, with gross margin swinging to 8.1% and R&D expenses exceeding revenue by over fivefold, driving a net loss of -$820.8M.
BioNTech is a leader in mRNA technologies, notably for co-developing the first approved mRNA COVID-19 vaccine with Pfizer.
The company is expected to outline focus areas and near- to longer-term milestones at the 44th Annual J.P. Morgan Healthcare Conference.
There is a bullish thesis on BioNTech SE highlighted by research platforms and value investing communities.
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 4, 2026 | -$3.70-54.3% vs -$2.40 | $121M-33.1% vs $180M |
Q2 2026 May 5, 2026 | -$2.43+4.4% vs -$2.54 | $136M-34.2% vs $207M |
Q2 2026 Mar 10, 2026 | -$1.44-556.7% vs -$0.22 | $1.1B+18.1% vs $902M |
Q4 2025 Nov 3, 2025 | -$0.14+87.5% vs -$1.12 | $1.8B+110.9% vs $844M |
BioNTech SE Sponsored ADR (NASDAQ: BNTX - Get Free Report) CEO Ugur Sahin sold 46,000 shares of BioNTech stock in a transaction that occurred on Tuesday, September 22nd. The shares were sold at an average price of $100.72, for a total value of $4,633,120.00. Following the sale, the chief executive officer directly owned 410,209 shares in
BioNTech SE Sponsored ADR (NASDAQ: BNTX - Get Free Report) CEO Ugur Sahin sold 33,000 shares of the business's stock in a transaction that occurred on Monday, September 21st. The shares were sold at an average price of $97.81, for a total value of $3,227,730.00. Following the transaction, the chief executive officer owned 456,209 shares of
BioNTech recently experienced a clinical trial failure, followed by a clinical success several weeks later. The company's deep pipeline could enable it to launch brand-new, lucrative products over the next few years.
BMO Capital Markets downgraded BioNTech and lowered its price target for the stock. The move came after BioNTech reduced its 2027 guidance and experienced a clinical setback.
Benchmark BNTX against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for BioNTech SE (BNTX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $98.46 | $24.73B | -19.18 | 0.2% | -39.59% | -5.65% | — | |
| $182.11 | $72.26B | -25.08 | -39.23% | -141.43% | -39.2% | — | |
| $28.17 | $160.55B | 20.71 | -1.65% | 6.81% | 4.87% | — | |
| $10.55 | $1.73B | 4.15 | 64.69% | -59.87% | — | — | |
| $13.30 | $378.03M | -5.54 | -51.43% | -391.9% | -46.54% | — | |
| $801.82 | $82.61B | 19.33 | 0.99% | 27.86% | 18.49% | — |
BioNTech SE (BNTX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when BNTX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
BioNTech SE (BNTX) stock FAQ — growth, dividends, profitability & financials explained
BioNTech SE (BNTX) reported $2.64B in revenue for fiscal year 2025. This represents a 4191% increase from $61.6M in 2017.
BioNTech SE (BNTX) grew revenue by 0.2% over the past year. Growth has been modest.
BioNTech SE (BNTX) reported a net loss of $1.69B for fiscal year 2025.
BioNTech SE (BNTX) has a return on equity (ROE) of -5.7%. Negative ROE indicates the company is unprofitable.
BioNTech SE (BNTX) generated $518.3M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
